| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 05/30/2006 | US7052875 stabilization of aqueous solutions of DNA by mixing with citric acid or tartaric acid and atelocollagen, and freeze drying; gene therapy |
| 05/30/2006 | US7052874 Killing microorganism; measurement, calibration antibiotic resistance |
| 05/30/2006 | US7052873 Natural human antibody |
| 05/30/2006 | US7052870 nucleotide sequences and complements that code mammalian targets of ripamycin (mTOR) and rapamycin insensitive companion of mammalian targets of ripamycin (rictor), used as screening targets for the identification and drugs which modulate the activity of enzymes |
| 05/30/2006 | US7052869 Obtaining a consensus protein from a group of amino acid sequences of a defined protein family |
| 05/30/2006 | US7052868 Human coagulation factor VII polypeptides |
| 05/30/2006 | US7052862 Lipoprotein associated phospholipase A2, inhibitors thereof and use of the same in diagnosis and therapy |
| 05/30/2006 | US7052860 Identification of Actinobacillus actinomycetemcomitans antigens for use in the diagnosis, treatment, and monitoring of periodontal diseases |
| 05/30/2006 | US7052856 Contacting a cell containing a NELL-1 gene with a test agent; and detecting a change in the expression level of Nell-1 gene as compared to the expression of the NELL-1 gene in a cell that is not contacted with test agent |
| 05/30/2006 | US7052850 Isolated human EDG-4 receptor |
| 05/30/2006 | US7052720 Spheroid preparation |
| 05/30/2006 | US7052705 Useful to control pathological angiogenesis, such as occurs in cancer and other diseases |
| 05/30/2006 | US7052704 Comprises fatty acid-conjugated products with disulfide linkage to proteins/peptides for delivery to cells; increases absorption and prolongs blood and tissue retention |
| 05/30/2006 | US7052703 T-cell receptorγ alternate reading frame protein, (TARP) and uses thereof |
| 05/30/2006 | US7052702 comprises a light-chain or a heavy-chain fragment of a Pseudonomas neurotoxin with a proteolytically active enzyme domain; N-acetylgalactosamine-binding lectins; to inhibit the release of neurotransmitters from neurons thereby reducing and/or preventing transmission of afferent pain signals |
| 05/30/2006 | US7052696 Antigenic epitopes and mosaic polypeptides of hepatitis C virus proteins |
| 05/30/2006 | US7052695 Angiopoietins and methods of treating hypertension |
| 05/30/2006 | US7052694 Immunoglobulin which specifically binds cell surface protein of nervous system tissue for preventing infections and treating tumors; anticarcinogenic agents; bactericides |
| 05/30/2006 | US7052693 Anti-human VEGF receptor FLT-1 monoclonal antibody |
| 05/30/2006 | US7052691 Vascular Endothelial Growth Factors (VEGF) by injection; for decreased serum glucose concentrations, improved glucose tolerance, increased insulin sensitivity, and reduced hyperinsulinemia |
| 05/30/2006 | US7052689 Preventing viral replication in cells; obtain cells, incubate with viricide, monitor cells for reduced viral activity |
| 05/30/2006 | US7052687 Human recombinant beta-interferon with improved solubility |
| 05/30/2006 | US7052686 Pegylated interleukin-10 |
| 05/30/2006 | US7052684 Methods of healing wounds and fibrotic disorders using IL-10 |
| 05/30/2006 | US7052683 comprising tris(hydroxymethyl)aminomethane, urea, beta-cyclodextrin and reduced glutathione; for absorbing hydrogen sulfide and carbon dioxide from the air |
| 05/30/2006 | US7052678 Particles for inhalation having sustained release properties |
| 05/30/2006 | US7052676 Interference with binding chemokines |
| 05/30/2006 | US7052674 Prokineticin polypeptides, related compositions and methods |
| 05/30/2006 | CA2288970C Use of microparticles having a protein and an antibody adsorbed thereon for preparing a pharmaceutical composition for intranasal administration |
| 05/30/2006 | CA2264718C Solid coprecipitates for enhanced bioavailability of lipophilic substances |
| 05/30/2006 | CA2242767C Glycosidase enzymes |
| 05/30/2006 | CA2087525C Adoptive immunotherapy with interleukin-7 |
| 05/29/2006 | CA2526684A1 Therapeutic peptides and method |
| 05/26/2006 | WO2006055973A2 Erythropoietin for treatment of multi-organ failure |
| 05/26/2006 | WO2006055871A2 Treatment for multiple sclerosis |
| 05/26/2006 | WO2006055743A2 Compbination growth therapy and cell therapy for treatment of acute and chronic diseases of the organs |
| 05/26/2006 | WO2006055422A2 Sampling device and methods |
| 05/26/2006 | WO2006055418A1 Cyclosporine for treating mucin deficiency |
| 05/26/2006 | WO2006055417A2 Methods for the therapeutic use of cyclosporine components |
| 05/26/2006 | WO2006055302A2 Method of treating myelodysplastic syndromes |
| 05/26/2006 | WO2006055264A1 Formulations, methods of production and uses of fgf-20 |
| 05/26/2006 | WO2006055103A1 Oxygenated albumin for use as blood and blood extender |
| 05/26/2006 | WO2006055077A2 Modulation of cd4+ t cell responses by a tick saliva protein, salp15 and polypeptides derived therefrom |
| 05/26/2006 | WO2006055024A2 Minicells as vaccines |
| 05/26/2006 | WO2006055008A2 Implantable sensors and implantable pumps and anti-scarring agents |
| 05/26/2006 | WO2006054961A2 Novel composition and methods for the treatment of immune related diseases |
| 05/26/2006 | WO2006054947A1 Novel antimicrobial peptides |
| 05/26/2006 | WO2006054931A1 The use and identification of antagonists of protease-activated receptor 3 (par3) in the treatment of asthma |
| 05/26/2006 | WO2006054908A1 Methods of immune or haematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer |
| 05/26/2006 | WO2006054839A1 Regulation of procaspase-2 activation by phosphorylation of procaspase-2 |
| 05/26/2006 | WO2006054801A1 New cyclic peptide compound |
| 05/26/2006 | WO2006054773A1 Activation of caspase in the cell division stage of cancer cells and utilization of caspase inhibitor in anticancer agent and so on |
| 05/26/2006 | WO2006054770A1 Novel map kinase kinase kinase (mapkkk) |
| 05/26/2006 | WO2006054641A1 Gpr7-selective ligand and use thereof |
| 05/26/2006 | WO2006054629A1 1-SUBSTITUTED-3-β-D-GLUCOPYRANOSYLATED NITROGENOUS HETERO- CYCLIC COMPOUNDS AND MEDICINES CONTAINING THE SAME |
| 05/26/2006 | WO2006054600A1 Novel protein and preventive/remedy for neurodegenerative disease such as polyglutamine disease using the same |
| 05/26/2006 | WO2006054396A1 Cyclic isodityrosine derivatives |
| 05/26/2006 | WO2006054304A2 Use of lipid conjugates in the treatment of disease |
| 05/26/2006 | WO2006054281A1 Compositions containing beta 2-glycoprotein i for the prevention and/or treatment of vascular disease |
| 05/26/2006 | WO2006054138A1 PEPTIDE ABLE TO BREAK THE m-p53/p63, m-p53/ p73 AND m-p53/RESPECTIVE ISOFORM PROTEINS COMPLEX FORMED IN THE TUMOR CELLS AND USES THEREOF IN THE PHARMACOLOGICAL FIELD |
| 05/26/2006 | WO2006054096A2 Soluble bifunctional proteins |
| 05/26/2006 | WO2006053923A1 Use of serine-proteinase known as ancrod in the treatment of duchenne muscular dystrophy |
| 05/26/2006 | WO2006053906A1 Soluble, stable insulin-containing formulations with a protamine salt |
| 05/26/2006 | WO2006053883A1 Fibronectin iii domain as leptin receptor antagonists |
| 05/26/2006 | WO2006053754A1 COMBINATIONS OF ANTI-ATHEROSCLEROTIC PEPTIDES AND AN mTOR INHIBITING AGENT AND THEIR METHODS OF USE |
| 05/26/2006 | WO2006053641A1 Prevention of vertical endoparasite infections |
| 05/26/2006 | WO2006053613A2 Skin care composition comprising fusion polypeptide composition |
| 05/26/2006 | WO2006053568A1 Tnf antagonists |
| 05/26/2006 | WO2006053565A2 Polypeptides having antimicrobial activity and polynucleotides encoding same |
| 05/26/2006 | WO2006053445A1 Lactic acid bacteria-derived bacteriocin and uses thereof for prevention or treatment of cancer |
| 05/26/2006 | WO2006053383A1 Bioactive compositions |
| 05/26/2006 | WO2006031786A3 Protein a compositions and methods of use |
| 05/26/2006 | WO2006010070A3 Compositions and methods related to peptides that selectively bind leukemia cells |
| 05/26/2006 | WO2006007881A3 New pharmaceutical compositions based on fluorenecarboxyclic acid esters and soluble tnf receptor fusion proteins |
| 05/26/2006 | WO2006006079A3 Methods for suppressing neovascularization using ephrinb2 |
| 05/26/2006 | WO2006004588A3 Immunodynamic complexes and methods for using and preparing such complexes |
| 05/26/2006 | WO2005120557A3 Inhibition of macrophage-stimulating protein receptor (ron) |
| 05/26/2006 | WO2005120542A3 Methods of treating disease with random copolymers |
| 05/26/2006 | WO2005118634A3 Helical peptidomimetics with enhanced activity against beta-amyloid production |
| 05/26/2006 | WO2005116657A3 Identification of ergothioneine transporter and therapeutic uses thereof |
| 05/26/2006 | WO2005115478A3 Methods and compositions for autism spectrum disorders |
| 05/26/2006 | WO2005115174A3 Alpha-msh-antagonist didpeptide conjugates |
| 05/26/2006 | WO2005099769A3 Novel g-csf conjugates |
| 05/26/2006 | WO2005089812A3 Novel antibiotic alternatives |
| 05/26/2006 | WO2005080338A3 New pharmaceutical compositions based on benzilic acid esters and soluble tnf receptor fusion proteins |
| 05/26/2006 | WO2005074633A3 Compositions and methods for characterizing, regulating, diagnosing, and treating cancer |
| 05/26/2006 | WO2005053727A3 Pharmaceutical compositions for bioactive peptide agents |
| 05/26/2006 | WO2004084835A3 Treating immunological disorder using agonists of interleukin-21/ interleukin-21 receptor |
| 05/26/2006 | WO2003100007A3 Eta-1 gene and methods for use |
| 05/26/2006 | CA2838516A1 Treatment of disease |
| 05/26/2006 | CA2629529A1 Plant extracts and dermatological uses thereof |
| 05/26/2006 | CA2588963A1 1-substituted-3-.beta.-d-glucopyranosylated nitrogenous hetero-cyclic compounds and medicines containing the same |
| 05/26/2006 | CA2588837A1 Erythropoietin for treatment of multi-organ failure |
| 05/26/2006 | CA2588145A1 Novel antimicrobial peptides |
| 05/26/2006 | CA2588093A1 Variants of pigment epithelium derived factor and uses thereof |
| 05/26/2006 | CA2588066A1 Roles for dual endothelin-1/angiotensin ii receptor (dear) in hypertension and angiogenesis |
| 05/26/2006 | CA2587948A1 Tnf antagonists |
| 05/26/2006 | CA2587921A1 Mutated netrin-4, fragments thereof and their use as medicines |
| 05/26/2006 | CA2587727A1 Methods of immune or haematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer |
| 05/26/2006 | CA2587398A1 Gpr7-selective ligand and use thereof |